For the past three years, a 72-year-old Medicare beneficiary with obesity and heart disease has had two options when it comes to GLP-1 medications: pay roughly $1,350 a month out of pocket, or go without. Starting July 1, 2026, a third option arrives. Under a new federal program called the Medicare GLP-1 Bridge, qualifying seniors will be able to fill a monthly prescription for Wegovy or Zepbound for a flat $50 copay.
That is not a typo, and it is not a coupon. The Centers for Medicare and Medicaid Services negotiated directly with Novo Nordisk and Eli Lilly to set the price, and the agency is routing prescriptions through a centralized claims processor that bypasses the traditional Part D system entirely. No prior authorization gauntlet. No plan-by-plan coverage lottery. For millions of older Americans who have watched these drugs reshape obesity treatment from the wrong side of a price wall, the Bridge is the first realistic path to access.
But it is also temporary. CMS designed the Bridge as an interim measure while it builds a larger initiative called BALANCE, which will eventually test new payment and delivery models for obesity care across Medicare and Medicaid. The agency has not set a firm end date for the Bridge or a launch date for BALANCE, which means seniors who start therapy this summer are stepping onto a platform that could shift beneath them.
Who qualifies and what the Bridge covers
CMS has published eligibility rules and a product list on its official Bridge program page. To enroll, a beneficiary must meet body mass index thresholds and carry at least one qualifying comorbidity. The two conditions that anchor the program are cardiovascular disease and moderate-to-severe obstructive sleep apnea, both of which now have FDA-approved GLP-1 treatment indications.
Three product lines are eligible for the $50 monthly copay:
- Wegovy (semaglutide), manufactured by Novo Nordisk. Approved to reduce the risk of major cardiovascular events in adults with obesity or overweight who also have established heart disease.
- Zepbound (tirzepatide) KwikPen formulations, manufactured by Eli Lilly. Approved for moderate-to-severe obstructive sleep apnea in adults with obesity.
- Foundayo, a newer Novo Nordisk formulation in the same GLP-1 class. It is included on the Bridge’s covered product list, though it is less well known than Wegovy and some beneficiaries may not yet recognize the name. Patients should ask their prescriber whether it is appropriate for their specific indication.
One structural detail matters enormously here: claims will not run through traditional Part D plans. CMS is processing prescriptions centrally, which means private insurers will not carry the financial risk for these fills. That gives the agency direct control over pricing, data collection, and cost-sharing in a way that Part D’s fragmented landscape of thousands of plan variations has never allowed.
The program is open to Medicare beneficiaries broadly, but CMS has not yet clarified every edge case. Seniors enrolled in Medicare Advantage plans, for instance, should confirm with CMS or their provider whether the centralized processor applies to them in the same way it does to traditional Medicare enrollees.
The FDA approvals that made this legally possible
Medicare has been statutorily barred from covering drugs prescribed primarily for weight loss for decades. The Bridge does not change that law. Instead, it works within it by tying coverage to specific disease indications rather than to weight reduction itself.
The clinical foundation for Wegovy’s cardiovascular indication comes from the SELECT trial, a randomized study of more than 17,600 participants published in the New England Journal of Medicine in November 2023. Researchers found that major adverse cardiovascular events (heart attack, stroke, or cardiovascular death) occurred in 6.5% of participants taking semaglutide compared with 8% in the placebo group. That 20% relative risk reduction gave the FDA enough evidence to grant the expanded label.
Zepbound’s sleep apnea approval, granted by the FDA in December 2024, was based on improvements in the apnea-hypopnea index, which measures how often breathing stops or becomes shallow during sleep. At 52 weeks, patients with severe sleep apnea and significant excess weight saw meaningful reductions, offering a treatment pathway that did not require a CPAP machine.
These on-label indications are what allow CMS to classify Bridge prescriptions as treatments for heart disease and sleep apnea, with weight loss understood as the mechanism rather than the stated purpose. It is a legal and regulatory distinction, but it is the reason the program can exist at all under current statute.
How the $50 price was set
According to the CMS Innovation Center’s overview of its GLP-1 affordability strategy, the agency completed negotiations with both Eli Lilly and Novo Nordisk to set pricing terms for the Bridge. The full details of those agreements have not been made public, but the $50 copay signals that both manufacturers accepted substantial discounts from their list prices, likely in exchange for guaranteed volume from a large, centralized federal payer.
CMS has framed the Bridge as more than a coverage expansion. In its voluntary model announcement, the agency said the program would “expand access to life-changing medicines” while generating real-world outcomes data across regions and demographics. By fixing the copay and centralizing claims, CMS can track utilization, adherence, and clinical results in a way that the current Part D system simply cannot. The Bridge is, in effect, a massive observational study with a built-in treatment arm.
Five things CMS has not answered yet
The Bridge launches in weeks, but several critical questions remain open as of June 2026. Beneficiaries should understand what is still uncertain before assuming the program will work seamlessly from day one.
Enrollment scale and cost. CMS has not published projections for how many of Medicare’s roughly 67 million beneficiaries might qualify. Without those numbers, it is impossible to estimate the program’s total cost or whether the negotiated pricing can hold if demand far exceeds expectations.
Supply chain capacity. GLP-1 supply constraints have plagued the commercial market for more than two years. Lower-dose starter pens, which are essential for safe dose titration, have been especially scarce. Neither Eli Lilly nor Novo Nordisk has publicly confirmed that manufacturing capacity can absorb a wave of new Bridge prescriptions on top of existing commercial and international demand.
The compounding market collision. Millions of Americans, including many seniors, have turned to compounded versions of semaglutide and tirzepatide as cheaper alternatives. The FDA has been tightening enforcement against compounding pharmacies producing these copies, and the Bridge’s launch coincides with that crackdown. Whether the $50 copay pulls patients away from compounded products, and whether brand-name supply can absorb them if it does, is an open question with real safety implications.
Medicaid and state-level coordination. The Bridge operates within Medicare, but the broader BALANCE model is designed to span both Medicare and Medicaid. Medicaid eligibility rules and benefit structures vary dramatically by state, and CMS has not explained how state programs will coordinate with the federal Bridge. That gap could create stark disparities: a 68-year-old on Medicare gets Wegovy for $50, while a 55-year-old on Medicaid in the same city has no comparable access.
What happens when the Bridge ends. CMS has repeatedly called this a short-term measure but has not set a firm sunset date or specified when BALANCE will be ready to absorb participants. For patients on chronic therapy, that ambiguity is not just administrative. Abruptly stopping GLP-1 medications is associated with rapid weight regain and metabolic rebound. If BALANCE faces delays, seniors who start therapy this summer could face coverage gaps or sudden cost spikes with no clear fallback.
What to do before July 1 if you think you qualify
Beneficiaries who believe they may be eligible should not wait until the program launches to start preparing. The most important step right now is scheduling a visit with a primary care physician or endocrinologist to establish a documented diagnosis of cardiovascular disease or obstructive sleep apnea, along with a current BMI measurement. Those records will be essential for meeting the Bridge’s eligibility criteria.
Providers will also need to determine which medication and starting dose is appropriate. Both Wegovy and Zepbound require titration schedules that begin at lower doses and increase gradually over several months, so patients who enroll on July 1 will not immediately be on a full therapeutic dose.
One practical question worth raising with your doctor: if you currently take Ozempic (semaglutide) for type 2 diabetes, switching to Wegovy through the Bridge may involve clinical considerations around dosing and indication that your prescriber should evaluate.
CMS has directed beneficiaries and providers to the official Bridge program page for enrollment details, including how prescriptions will be submitted through the centralized claims processor.
A real opening, with real limits
The GLP-1 Bridge is the most significant expansion of Medicare drug access in years, and for seniors who meet the criteria, the math is straightforward: $50 a month instead of $1,350, with no Part D middleman. That is a genuine, material change in who can afford these medications.
But the program is an experiment, not an entitlement. Its durability depends on factors that CMS, Congress, and the drug manufacturers have not yet resolved, from supply chain capacity to the timeline for BALANCE to the political will to keep funding a program that could cost billions if enrollment scales quickly. Seniors who enroll should do so understanding both what the Bridge offers today and how much remains unbuilt beneath it.
Warren Cohen is a finance writer based in Phoenix, Arizona, covering personal finance topics including credit, banking, and beginner investing. He earned his degree in business administration from Arizona State University and began his career working in consumer finance, where he gained direct experience with lending and credit systems. He now writes for personal finance websites and fintech platforms, focusing on clear, practical content that helps readers make informed financial decisions.
